1. Home
  2. HOMB vs CYTK Comparison

HOMB vs CYTK Comparison

Compare HOMB & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOMB
  • CYTK
  • Stock Information
  • Founded
  • HOMB 1998
  • CYTK 1997
  • Country
  • HOMB United States
  • CYTK United States
  • Employees
  • HOMB N/A
  • CYTK N/A
  • Industry
  • HOMB Major Banks
  • CYTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • HOMB Finance
  • CYTK Health Care
  • Exchange
  • HOMB Nasdaq
  • CYTK Nasdaq
  • Market Cap
  • HOMB 5.6B
  • CYTK 4.6B
  • IPO Year
  • HOMB 2006
  • CYTK 2004
  • Fundamental
  • Price
  • HOMB $28.95
  • CYTK $49.76
  • Analyst Decision
  • HOMB Hold
  • CYTK Buy
  • Analyst Count
  • HOMB 6
  • CYTK 15
  • Target Price
  • HOMB $31.83
  • CYTK $75.57
  • AVG Volume (30 Days)
  • HOMB 876.1K
  • CYTK 2.7M
  • Earning Date
  • HOMB 10-15-2025
  • CYTK 11-05-2025
  • Dividend Yield
  • HOMB 2.72%
  • CYTK N/A
  • EPS Growth
  • HOMB 14.00
  • CYTK N/A
  • EPS
  • HOMB 2.19
  • CYTK N/A
  • Revenue
  • HOMB $1,007,568,000.00
  • CYTK $85,738,000.00
  • Revenue This Year
  • HOMB $12.79
  • CYTK $330.96
  • Revenue Next Year
  • HOMB $2.65
  • CYTK $73.41
  • P/E Ratio
  • HOMB $13.44
  • CYTK N/A
  • Revenue Growth
  • HOMB 3.66
  • CYTK 2635.74
  • 52 Week Low
  • HOMB $24.22
  • CYTK $29.31
  • 52 Week High
  • HOMB $32.91
  • CYTK $59.39
  • Technical
  • Relative Strength Index (RSI)
  • HOMB 46.01
  • CYTK 63.01
  • Support Level
  • HOMB $29.06
  • CYTK $49.22
  • Resistance Level
  • HOMB $30.25
  • CYTK $53.58
  • Average True Range (ATR)
  • HOMB 0.59
  • CYTK 2.54
  • MACD
  • HOMB -0.08
  • CYTK 0.29
  • Stochastic Oscillator
  • HOMB 9.71
  • CYTK 76.53

About HOMB Home BancShares Inc.

Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The bank also emphasizes attracting experienced bankers, credit quality and a solid balance sheet. The bank's main source of net revenue is net interest income.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: